Acamprosate: a new pharmacotherapeutic approach to relapse prevention in alcoholism--preliminary data.
The efficacy of the homotaurine-derivative acamprosate (calcium acetylhomotaurinate) to increase abstinence rates in weaned alcoholics was examined in a placebo-controlled double-blind multicentre study involving 272 subjects. Preliminary results indicate a significantly higher abstinence rate during and at the end of the study (42.8% vs. 20.7%, p < 0.01), a higher number of abstinent days and a lower drop-out rate in the treated than in the placebo group.
Soyka
M
M
Psychiatric Hospital, University of Munich, Germany.
Sass
H
H
D000077443:Acamprosate; D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000188:drug therapy* / Q000201:enzymology; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013695:Temperance; D005723:gamma-Glutamyltransferase / Q000097:blood
D013654:Taurine; D005723:gamma-Glutamyltransferase; D000077443:Acamprosate